share_log

Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock

Benzinga ·  Jan 3 03:00

Ratings for Capricor Therapeutics (NASDAQ:CAPR) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings52000
Last 30D10000
1M Ago00000
2M Ago21000
3M Ago21000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.71, a high estimate of $77.00, and a low estimate of $30.00. This upward trend is evident, with the current average reflecting a 3.69% increase from the previous average price target of $51.80.

bigjpg

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment